Professional
Added to YB: 2024-11-12
Pitch date: 2024-11-04
BCRX [bullish]
BioCryst Pharmaceuticals, Inc.
+1.36%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases.
Market Cap
$1.7B
Pitch Price
$7.38
Price Target
10.00 (+34%)
Dividend
N/A
EV/EBITDA
25.98
P/E
-149.16
EV/Sales
3.58
Sector
Biotechnology
Category
growth
Show full summary:
BioCryst Pharmaceuticals, Inc. - $BCRX
BCRX: Orladeyo Q3 rev $116M (+7% q/q), beating est. On track for 2026 EPS/CF+ & $1B peak sales. Undervalued at $1.8B mkt cap w/ $352M cash. New competition concerns overblown due to first-mover advantage. Pipeline upside w/ BCX17725 & Avoralstat data by 25YE. PT $10.
Read full article (8 min)